SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Carlson, W.
Right arrow Articles by Oberg, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Carlson, W.
Right arrow Articles by Oberg, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Clinical Pharmacology of Carvedilol

William Carlson

Brigham and Women's Hospital, Harvard Medical School

Kristin Oberg

School of Pharmacy, Northeastern University, Boston, MA

Background: There is now a wealth of data supporting the use of beta-blockers in heart failure and the additional pharmacological properties of carvedilol are thought to play an important role in the therapeutic efficacy of carvedilol in this disease.

Methods and Results: Carvedilol is licensed for the treatment of essential hypertension, chronic stable angina, and mild to moderate chronic heart failure. This article provides an up-to-date review of the clinical pharmacology of carvedilol, with particular emphasis on its clinical effects in heart failure.

Conclusion: Carvedilol is a multiple-action neurohormonal antagonist that offers non selective beta-blockade, alpha-1 blockade, antioxidant, anti-ischemic mortality, and anti proliferative properties. In addition to reductions in hospitalization and mortality rates, benefits of carvedilol in heart failure include dramatic improvements in left ventricular function and other parameters of cardiac remodeling.

Key Words: nonselective beta-blockade • {alpha}-1 blockade • heart failure • carvedilol.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 4, No. 4, 205-218 (1999)
DOI: 10.1177/107424849900400402
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
H. J. Dargie and The CAPRICORN Steering Committee
Design and methodology of the CAPRICORN trial -- a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction
Eur J Heart Fail, September 1, 2000; 2(3): 325 - 332.
[Full Text] [PDF]


Advertisement